Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Rhea-AI Summary

Pacira (Nasdaq: PCRX) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a live conference call and webcast at 4:30 p.m. ET following the release.

Investors who wish to ask questions by phone must pre-register to receive dial-in details and a PIN. A live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible on the Pacira website for about two weeks after the call.

BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com 

FAQ

When will Pacira (PCRX) report its third quarter 2025 results?

Pacira will report Q3 2025 results after the U.S. market close on Thursday, November 6, 2025.

What time is the Pacira (PCRX) conference call and webcast on November 6, 2025?

The live conference call and webcast will begin at 4:30 p.m. ET on November 6, 2025.

How do I join the Pacira (PCRX) Q3 2025 call and ask questions by phone?

Pre-register for the call to receive dial-in information and a PIN that enables participation in the Q&A by phone.

Where can I find the Pacira (PCRX) webcast for the Q3 2025 results?

The live audio webcast and replay are available via the Events page at investor.pacira.com.

How long will the Pacira (PCRX) webcast replay be available after the Q3 2025 call?

A replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

Can international investors access the Pacira (PCRX) Q3 2025 webcast?

Yes; the live audio webcast is available online via the company’s investor website and requires no phone registration to listen.